X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2850) 2850
science & technology (2609) 2609
life sciences & biomedicine (2517) 2517
male (1640) 1640
pyridones - administration & dosage (1565) 1565
pyridones - therapeutic use (1504) 1504
female (1416) 1416
administration, oral (969) 969
animals (897) 897
middle aged (843) 843
pyridones - adverse effects (829) 829
aged (814) 814
pyridones - pharmacology (807) 807
adult (688) 688
treatment outcome (651) 651
pharmacology & pharmacy (602) 602
pyrazoles - therapeutic use (574) 574
pyrazoles - administration & dosage (554) 554
anticoagulants (524) 524
anticoagulants - therapeutic use (485) 485
rivaroxaban (461) 461
cardiovascular system & cardiology (454) 454
anticoagulants - administration & dosage (441) 441
abridged index medicus (429) 429
pyrazoles - adverse effects (416) 416
dabigatran (402) 402
atrial fibrillation - drug therapy (395) 395
pyridones - pharmacokinetics (381) 381
apixaban (365) 365
anticoagulants - adverse effects (361) 361
hematology (361) 361
stroke - prevention & control (350) 350
atrial fibrillation (342) 342
dose-response relationship, drug (325) 325
general & internal medicine (315) 315
cardiac & cardiovascular systems (307) 307
aged, 80 and over (302) 302
rats (302) 302
hemorrhage - chemically induced (300) 300
analysis (294) 294
care and treatment (294) 294
drug therapy (287) 287
adolescent (285) 285
mice (273) 273
medicine, general & internal (265) 265
atrial fibrillation - complications (264) 264
oncology (263) 263
beta-alanine - analogs & derivatives (255) 255
deferiprone (255) 255
drug therapy, combination (255) 255
risk factors (249) 249
stroke (247) 247
iron chelating agents - therapeutic use (246) 246
clinical trials (230) 230
morpholines - therapeutic use (227) 227
rivaroxaban - therapeutic use (217) 217
warfarin (216) 216
warfarin - therapeutic use (215) 215
medicine & public health (210) 210
time factors (210) 210
thiophenes - therapeutic use (209) 209
research (208) 208
peripheral vascular disease (207) 207
rivaroxaban - administration & dosage (207) 207
benzimidazoles - therapeutic use (206) 206
retrospective studies (206) 206
young adult (205) 205
patients (198) 198
thromboembolism (193) 193
milrinone (190) 190
pyridones - chemistry (189) 189
dabigatran - administration & dosage (181) 181
dabigatran - therapeutic use (179) 179
iron chelating agents - administration & dosage (177) 177
pyrimidinones - administration & dosage (177) 177
imidazoles - administration & dosage (174) 174
neurosciences & neurology (174) 174
pirfenidone (173) 173
drug administration schedule (172) 172
randomized controlled trials as topic (171) 171
dosage and administration (170) 170
stroke - etiology (169) 169
factor xa inhibitors - administration & dosage (167) 167
double-blind method (166) 166
rivaroxaban - adverse effects (166) 166
morpholines - administration & dosage (163) 163
child (162) 162
melanoma - drug therapy (162) 162
beta-alanine - therapeutic use (161) 161
deferoxamine - therapeutic use (161) 161
idiopathic pulmonary fibrosis - drug therapy (160) 160
clinical trials as topic (154) 154
disease models, animal (153) 153
health aspects (152) 152
pyridines - therapeutic use (152) 152
warfarin - adverse effects (150) 150
respiratory system (149) 149
pyridones - blood (148) 148
warfarin - administration & dosage (148) 148
benzimidazoles - administration & dosage (147) 147
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3285) 3285
German (73) 73
Japanese (38) 38
French (29) 29
Spanish (23) 23
Italian (18) 18
Russian (7) 7
Czech (6) 6
Dutch (5) 5
Norwegian (5) 5
Chinese (4) 4
Hungarian (4) 4
Portuguese (4) 4
Danish (3) 3
Polish (3) 3
Swedish (3) 3
Finnish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 09/2014, Volume 64, Issue 11, pp. 1128 - 1139
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 09/2018, Volume 16, Issue 9, pp. 1891 - 1894
Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants | Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
The lancet oncology, ISSN 1470-2045, 10/2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Stroke (1970), ISSN 1524-4628, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | Clinical Neurology | Peripheral Vascular Disease | Neurosciences & Neurology | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies | Index Medicus
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2014, Volume 111, Issue 4, pp. 575 - 582
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article